Key Highlights

  • New AURORA 1 Phase 3 data for LUPKYNIS presented at EULAR 2026 Congress demonstrated strong lupus nephritis outcomes, with the latest quarter delivering 24% revenue growth year-over-year and net profit growth of 47%.
  • Technical momentum is strongly bullish, with six of six moving averages signalling buy, as AUPH approaches its 52-week high of $16.88 from the June 18 close of $16.46.
  • AUPH is trading at $17.58 pre-market June 22, up 6.79%, with a P/E of 7.62 on EPS of $2.16, reflecting genuine profitability at an undemanding multiple for a commercial-stage biotech.

Fundamentals, Data, and Technicals Align

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is trading at $17.58 pre-market June 22, up 6.79% from the June 18 close of $16.46. Aurinia is a commercial-stage biopharmaceutical company developing and commercialising innovative therapies for autoimmune diseases, with flagship product LUPKYNIS (voclosporin) as the first FDA-approved oral therapy for active lupus nephritis.

The pre-market advance reflects a rare convergence of three independent positive signals. First, new AURORA 1 Phase 3 data presented at the EULAR 2026 Congress showcased LUPKYNIS outcomes in lupus nephritis patients, adding clinical depth to the commercial story with an audience of the world's leading rheumatologists. Second, the latest quarterly financial results demonstrated 24% revenue growth year-over-year and net profit growth of 47%, confirming that LUPKYNIS is scaling commercially with improving profitability. Third, the technical picture is uniformly constructive, with all six major moving averages on a buy signal and the stock approaching its 52-week high of $16.88. Beyond LUPKYNIS, Aurinia is advancing aritinercept, a dual inhibitor of B cell-activating factor and APRIL, in clinical development for multiple autoimmune indications, providing pipeline optionality beyond the commercial anchor.

Valuation and Risk Considerations

AUPH trades at a P/E of 7.62 on EPS of $2.16, a notably low multiple for a commercial-stage biotechnology company with 24% revenue growth and 47% profit growth. The 52-week range of $7.29 to $16.88 reflects the commercial ramp from earlier-stage investor hesitation. Key risks include the pace of LUPKYNIS adoption in a nephrology market requiring specialist engagement and competition from other lupus nephritis therapies.

Conclusion

Aurinia is one of the few names in the pre-market healthcare movers list with confirmed profitability, revenue growth, and a technical breakout signal simultaneously, making the 6.79% pre-market advance a fundamentally supported move.